COVID-19: IgG seroconversion under intensive glucocorticoid treatment in a high-risk patient with minimal change disease

1Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this case report we present a rare case of a patient with multiple risk factors for severe coronavirus disease (COVID 19) in whom intensive glucocorticoid treatment due to incipient nephrotic syndrome coincided with SARS-CoV‑2 infection. Despite this high baseline risk profile and the use of glucocorticoids the patient developed only mild disease including IgG SARS-CoV‑2 seroconversion.

Cite

CITATION STYLE

APA

Eder, M., Strassl, R., Kläger, J., Aigner, C., Thalhammer, F., & Kikić, Ž. (2021). COVID-19: IgG seroconversion under intensive glucocorticoid treatment in a high-risk patient with minimal change disease. Wiener Klinische Wochenschrift, 133(7–8), 412–413. https://doi.org/10.1007/s00508-020-01776-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free